Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next? Five Things To Look Out For In February

Alvotech Puts Adalimumab In Its Sights; AAM Meeting Hits Florida

Executive Summary

Generics Bulletin previews the most noteworthy and anticipated events for February 2024.

You may also be interested in...



Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share

A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.

Alvotech Lines Up US Biosimilar Approvals After FDA Inspection

Alvotech has revealed details of exactly when it expects to win US FDA approvals for its Teva-partnered Humira and Stelara biosimilars, after an agency reinspection of its manufacturing plant in Reykjavik, Iceland resulted in just a single “readily addressable” Form 483 observation.

Celltrion Reveals 2030 Ambition Amid 80mg High-Concentration Adalimumab Launch

Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel